NICE is unable to make a recommendation about the use in the NHS of adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer in adults. After the first committee meeting, the technology appraisal committee’s preferred assumptions included using overall survival data from the KYRSTAL-12 trial in the economic model.
Because this data is immature, Bristol Myers Squibb will consider restarting the evaluation of this technology when the final overall survival analysis can be included in the economic model.
As a result, we are terminating this appraisal.